The future of private equity investment in healthcare
Private equity investment in healthcare has been a driving force behind growth in the sector in recent years (read our article on the topic), and despite COVID-19, the capital available for investment is at record levels. Structural change will always create opportunity as well as challenges, and private equity should be well placed to help businesses emerge strongly and take advantage of the opportunities.
However, just as the lockdown phase which has started to pass has no precedent in our times, so the months ahead will bring market conditions which none of us has encountered before. What might be coming next, and how can PE play a part?
Watch the recording of this 1 hour webinar where we interviewed three senior PE investors who shared their views on the current investment environment, and the outlook as we reach a new equilibrium, providing you with insights to help you thrive in 2020 and beyond.
We were joined by Jane Grewar, Operating Partner at Limerston Capital, Kevin Keck, Partner at Phoenix Private Equity and Ben Long, Partner at Inflexion.
JANE GREWAR OPERATING PARTNER AT LIMERSTON CAPITAL
Jane Grewar is an Operating Partner at Limerston Capital, a private equity firm with over £300 million under management. Over half the fund invested in healthcare and life sciences and they continue to actively invest in the sector. Within the portfolio they have Arch Sciences, a leading provider of analytical chemistry services to the UK and US pharma industry amongst others. Previously, Jane was in the Pharma and Life Sciences practice at McKinsey where she led commercial growth programmes for big pharma. Jane started her career as a qualified doctor with the NHS.
BEN LONG, PARTNER AT INFLEXION
Ben Long is a Partner at Inflexion, a mid-market private equity firm, investing in high growth, entrepreneurial businesses across all sectors from offices in London and Manchester. Ben has been in Private Equity since 2006 and has specialised in healthcare for almost 10 years, leading investments into businesses including Pharmaspectra, European LifeCare Group and Lintbells.
KEVIN KECK, PARTNER AT PHOENIX EQUITY PARTNERS
Kevin Keck is a Partner at Phoenix Equity Partners, a leading growth-focused private equity firm, investing in UK private companies valued at up to £150m. Kevin leads Phoenix’s investment in the healthcare, education and media sectors, and is a Non-executive Director at Rayner Surgical Group, Sygnature Discovery and Nineteen Events.